1. Home
  2. CYCU vs MRKR Comparison

CYCU vs MRKR Comparison

Compare CYCU & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$2.43

Market Cap

17.8M

Sector

N/A

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$2.10

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
MRKR
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
16.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CYCU
MRKR
Price
$2.43
$2.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$7.00
$10.17
AVG Volume (30 Days)
147.3K
547.5K
Earning Date
02-24-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,667,874.00
$4,694,988.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.13
$0.81
52 Week High
$2,028.87
$4.07

Technical Indicators

Market Signals
Indicator
CYCU
MRKR
Relative Strength Index (RSI) 38.52 63.59
Support Level $2.29 $1.93
Resistance Level $2.91 $2.29
Average True Range (ATR) 0.25 0.26
MACD -0.02 0.01
Stochastic Oscillator 17.90 60.92

Price Performance

Historical Comparison
CYCU
MRKR

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: